Search bioRxivSearch

bioRxiv · 10.1101/632638

The Emerging Gait Dysfunction Phenotype in Idiopathic Parkinson’s Disease

Abstract

ObjectiveSeverity of motor symptoms in Parkinsons disease (PD), and rate of change of these symptoms, suggests the existence of disease subgroups. One important PD subgroup is defined by postural instability and gait dysfunction (PIGD), which is associated with disability, lower quality of life, and cognitive deterioration. In this study, we evaluate what clinical factors at baseline are associated with early development of postural instability in PD.\n\nMethodsData was downloaded from the Parkinsons Progressive Markers Initiative (PPMI). Several clinical features predict development of postural instability. We provisionally term the associated phenotype the emerging gait disorder (eGD) phenotype. We evaluate validity of the phenotype in two held-out populations.\n\nResultsIndividuals with the proposed eGD phenotype have a significantly higher risk of developing postural instability in both validation sets (p < 0.00001 in both sets). The proposed eGD phenotype occurred before development of postural instability (HY stage [&ge;] 3) in 289 of 301 paired comparisons (Fischer Exact Test, p < 0.000001), with a median progression time from development of eGD phenotype to postural instability of 972 days. Individuals with the proposed eGD phenotype at baseline had more rapid cognitive decline as measured by the Montreal Cognitive Assessment (p = 0.002) and Hopkins Verbal Learning Test (Total Recall, p = 0.008).\n\nInterpretationWe describe a clinical phenotype, detectable at baseline in a subset of individuals with PD, that is associated with accelerated development of postural instability. Within the sample, development of the eGD phenotype reliably precedes development of disability, and is a harbinger of more rapid cognitive progression.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Skidmore, F., Monroe, W., Hurt, C., Nicholas, A., Gerstenecker, A., Anthony, T., Jololian, L., Cutter, G., Bashir, A., Denney, T., Standaert, D., Disbrow, E.. 2019-05-17. The Emerging Gait Dysfunction Phenotype in Idiopathic Parkinson’s Disease. https://doi.org/10.1101/632638

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience